Vertex Pharma (VRTX) Misses Q4 EPS by 4c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
February 10, 2025 4:01 PM ESTFull year product revenue of $11.02 billion, a 12% increase compared to full year 2023
Company provides full year 2025 total revenue guidance of $11.75 to $12.0 billion
ALYFTREK approved in the U.S. for patients ages 6+ with cystic fibrosis; JOURNAVX approved in the U.S. for moderate-to-severe acute pain
Diverse late-stage clinical pipeline accelerates with four programs in pivotal development
Stuart Arbuckle, Chief Operating Officer, announces intent to retire July 1, 2025; as part of planned transition, Charlie Wagner, Chief Financial Officer, to assume additional role of Chief Operating... More
